The prognostic significance of whole blood global and specific DNA methylation levels in gastric adenocarcinoma by M.S. Al-Moundhri et al.
The Prognostic Significance of Whole Blood Global and
Specific DNA Methylation Levels in Gastric
Adenocarcinoma
Mansour S. Al-Moundhri1*, Maryam Al-Nabhani2, Letizia Tarantini3, Andrea Baccarelli3, Jennifer A.
Rusiecki4
1Medical Oncology Unit, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University (SQU), Muscat, Sultanate of Oman, 2Department of
Genetics, College of Medicine and Health Sciences, Sultan Qaboos University (SQU), Muscat, Sultanate of Oman, 3Center of Molecular and Genetic Epidemiology,
Department of Environmental and Occupational Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and Universita` degli Studi di Milano, Milan, Italy,
4Department of Preventive Medicine and Biometrics, Uniformed Services University, Bethesda, Maryland, United States of America
Abstract
Background: Epigenetics, particularly DNA methylation, has recently been elucidated as important in gastric cancer (GC)
initiation and progression. We investigated the clinical and prognostic importance of whole blood global and site-specific
DNA methylation in GC.
Methods: Genomic DNA was extracted from the peripheral blood of 105 Omani GC patients at diagnosis. DNA methylation
was quantified by pyrosequencing of global DNA and specific gene promoter regions at 5 CpG sites for CDH1, 7 CpG sites
for p16, 4 CpG sites for p53, and 3 CpG sites for RUNX3. DNA methylation levels in patients were categorized into low,
medium, and high tertiles. Associations between methylation level category and clinicopathological features were
evaluated using x2 tests. Survival analyses were carried out using the Kaplan-Meier method and log rank test. A backward
conditional Cox proportional hazards regression model was used to identify independent predictors of survival.
Results: Older GC patients had increased methylation levels at specific CpG sites within the CDH1, p53, and RUNX-3
promoters. Male gender was significantly associated with reduced global and increased site-specific DNA methylation levels
in CDH1, p16, and p53 promoters. Global DNA low methylation level was associated with better survival on univariate
analysis. Patients with high and medium methylation vs. low methylation levels across p16 promoter CpG sites, site 2 in
particular, had better survival. Multivariate analysis showed that global DNA hypermethylation was a significant
independent predictor of worse survival (hazard ratio (HR) = 2.0, 95% CI: 1.1–3.8; p= 0.02) and high methylation mean
values across p16 promoter sites 1–7 were associated with better survival with HR of 0.3 (95% CI, 0.1–0.8; p= 0.02)
respectively.
Conclusions: Analysis of global and site-specific DNA methylation in peripheral blood by pyrosequencing provides
quantitative DNA methylation values that may serve as important prognostic indicators.
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Introduction
Gastric cancer (GC) is a common malignancy that is a leading
cause of cancer mortality worldwide [1]. GC has been linked to
Helicobacter infection and environmental exposures including:
smoking, salted fish, and low intake of fruit and vegetables
[2,3,4,5]. While these exposures are very common, very few
exposed individuals develop GC. Therefore, it has been postulated
that genetic factors such as single nucleotide polymorphisms in
genes in several cellular pathways may increase GC risk
[2,3,4,5,6,7,8]. In addition, studies have recently begun to
elucidate the role of epigenetics, in particular DNA methylation,
in GC initiation and progression [9,10,11]. Global DNA
hypomethylation is associated with genomic instability, while
DNA hypermethylation at CpG islands in or near gene promoter
regions is associated with gene ‘‘silencing’’ [10,12,13]. Global
genomic DNA methylation in cancerous gastric tissues has been
found to be significantly lower than in non-cancerous tissues and
shows a gradual increase in hypomethylation from normal gastric
mucosa to chronic atrophic gastritis, severe, and intestinal
metaplasia [10,12,13]. Global DNA hypomethylation occurs at
an early stage in gastric carcinogenesis and may therefore serve as
a novel biomarker of gastric neoplasia [12]. In contrast, several
genes have been found to exhibit promoter hypermethylation
resulting in gene silencing in GC. It has been suggested that the
hypermethylation of the tumor suppressor genes, RUNX3 and
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TSLC1, may have value as molecular diagnostic markers, and
hMLH1 and p16 methylation may predict stomach cancer risk
[14]. CDH1 promoter hypermethylation frequently occurs in
gastric carcinomas with a diffuse histotype and is significantly
associated with down-regulated E-cadherin expression [15].
The potential diagnostic and prognostic value of promoter
hypermethylation in the tissue and serum of patients with GC has
been shown, particularly for the promoters of the p16, CDH1,
GSTP1, and APC genes [16,17]. More recently, the use of non-
target tissue such as whole blood has been suggested as a useful
biomarker in cancers such as gastric, lung, breast, bladder, and
head and neck cancers [18,19,20,21,22]. Hou et al demonstrated
that LINE-1 hypomethylation increased gastric cancer risk [OR
=1.4 (95% CI = (0.9–2.0)] [18]. Hsiung et al found that
hypomethylation LRE1 sequence resulted in a significant increase
risk for head and neck cancer in a case-control study[19].
Moreover, in another case-control study, there was an association
between leukocyte DNA hypomethylation with increased risk of
developing bladder cancer, independent of smoking and other
assessed risk factors[21]. Global DNA hypomethylation and locus-
specific methylation patterns in peripheral blood DNA were found
to be a potential surrogate markers for breast cancer risk [20,22].
Therefore, with above data suggesting usefulness of analysis of
global and specific methylation and cancer risk predisposition
coupled with prognostic data in target tissue and serum, we
studied the prognostic significance of whole blood DNA
methylation levels both globally (estimated in LINE-1 repeated
elements) and in the promoter regions of the p16, CDH1, p53,
and RUNX3 genes using pyrosequencing in an Omani GC
population.
Materials and Methods
Study participants
The study population consisted of a series of unrelated GC
patients who were diagnosed between 2004–2008 at two main
hospitals in the Sultanate of Oman (Sultan Qaboos University
Hospital and Royal Hospital). The Medical Research and Ethics
Committee of the College of Medicine of Sultan Qaboos
University and the Institutional Review Board of the Uniformed
Services University approved the study design. Participants of this
study as part of epigenetics of gastric cancer in Oman project were
provided with informed written consent prior to study participa-
tion in compliance with the Declaration of Helsinki.
Blood Collection and DNA extraction
Ten milliliters of blood was collected from each participant in
an EDTA tube and stored frozen until DNA extraction at time of
diagnosis or referral to the treating center for consideration for
chemotherapy or chemo-radiotherapy. Whole blood DNA
extraction was performed using a commercial kit (Gentra Pure-
gene DNA Purification kit, Qiagen, Gaithersburg, MD, USA) and
stored until processing for analysis.
Bisulfite treatment. Five hundred nanograms of genomic
DNA was treated using the EZ DNA Methylation-Gold Kit
(D5007, Zymo Research, Orange, CA, USA) according to the
manufacturer’s instructions. The bisulfite-treated DNA was eluted
with 30 ml MElution buffer. Several methods exist to measure
DNA methylation. Recently, a new bisulfite-based PCR method
was developed to assess global DNA methylation using amplified
repetitive LINE-1 elements that are normally heavily methylated
[23]. Since it is estimated that more than one-third of DNA
methylation occurs in repetitive elements, analyzing repetitive
element methylation can serve as a surrogate marker for global
genomic DNA methylation [23]. The same method can be used to
measure CpG island methylation in gene promoter regions.
PCR and Pyrosequencing. We performed 50 ml PCR
reactions using GoTaq Green Master mix (M7123, Promega,
Madison, WI, USA), 10 pmol each of forward and reverse
primers, and 50 ng bisulfite-treated genomic DNA (the primer
sequences and PCR conditions are shown in Table 1. The
gene-specific assays allowed for the analysis of multiple adjacent
CpG sites within the promoter regions of each gene. We measured
CpG methylation in genes at 5 sites in CDH1, 7 sites in p16, 4 sites
in p53, and 3 sites in RUNX3. In our statistical analysis, we
considered both site-specific and mean CpG methylation across
sites for each gene. The LINE-1 assay measured DNA methylation
at three adjacent CpG sites. Because the value of measuring
methylation at a single CpG site within repeated sequences is
undetermined, our statistical analysis considered only the
average methylation in the three LINE-1 CpG sites. DNA
methylation level was quantified using bisulfite-PCR and
pyrosequencing. Briefly, a biotin-labeled primer was used to
purify the final PCR product using Sepharose beads. The PCR
product was bound to Streptavidin Sepharose High Performance
(AmershamBiosciences, Uppsala, Sweden), purified, washed,
denatured with 0.2 mol/L NaOH, and washed again using the
Pyrosequencing Vacuum Prep Tool (Pyrosequencing, Inc.,
Westborough, MA) according to the manufacturer’s instructions.
Pyrosequencing primer (0.3 mM) was then annealed to the purified
single-stranded PCR product and pyrosequencing was performed
using the PyroMark Q96MD pyrosequencing system (Qiagen, Inc,
Hilden, Germany).
The cut-off values for discrimination of methylation levels for
global and specific whole blood DNA methylation were catego-
rized based as follows: low (,33 percentile), medium ($33 and
,66 percentile), and high ($66% percentile) (Table S1). In the
text, the terms ‘‘hypomethylation’’ and ‘‘hypermethylation’’ are
used interchangeably with words ‘‘low’’ and ‘‘high’’ methylation
respectively.
Statistical analysis
Associations between methylation level category and clinico-
pathological features were evaluated using x2 tests. Survival time
was defined as the interval between a biopsy-proven diagnosis and
death or the last known follow-up examination, whichever came
first. The date of death was obtained from medical records or
telephone contact. The Kaplan-Meier method was used to
estimate overall survival time, and statistical significance was
determined using the log-rank test. A backward conditional Cox
proportional hazards regression model was used for multivariate
analyses that included age (,50 years and $50 years), gender,
tumor depth of invasion (T1 and T 2 vs. T3 and T4), presence or
absence of lymph node metastases, overall stage (I and II vs. III
and IV), tumor differentiation (well vs. moderate and poor), use of
either chemotherapy or chemo-radiotherapy, and methylation
variables that showed a statistically significant association with
survival from univariate analysis. P-values less than 0.05 were
considered statistically significant. All data analyses were per-
formed using SPSS 16.0 software (SPSS, Chicago, IL, USA).
Results
One hundred and five GC patients that were diagnosed during
2004–2008 were included. The age range for the GC patients was
19–83 years. The means and standard deviations of patient was
56.2612.2. Sixty percent of participants were male and forty
percent were female.
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Global and specific DNA methylation levels in association
with clinicopathological features
Using x2 tests we examined the relationship between global and
specific DNA methylation levels age, gender and the following
cancer prognostic factors: T stage, lymph node involvement,
overall stage, and tumor differentiation (Table S1).
Older age ($50years) was associated with CDH1 promoter
hypermethylation at sites 3, 5, and on average across the five
CDH1sites, p53 promoter hypermethylation at site 3 and on
average across the four p53 sites, and RUNX3 promoter
hypermethylation at site 1.
Male gender was associated with Global DNA hypomethyla-
tion, CDH1 promoter hypermethylation at sites 2,3, 4,5, and on
average across the five CDH1sites, p16 promoter hypermethyla-
tion at sites 2 and 5 and hypomethylation at sites 3 and 6, p53
promoter hypermethylation at sites 1-4 and on average across the
four p53 sites.
In terms of tumor characteristics, advance T stage was
associated with RUNX3 promoter hypomethylation at site 3.
Lymph node involvement was associated with p53hypomethyla-
tion at sites 1, 3, 4 and on average across the four sites, and
RUNX3 promoter hypomethylation at site 2. Advanced overall
stage was associated with p16 promoter hypermethylation at site 5
and hypomethylation at p53 site 1.
We found no association between smoking status and
methylation patterns in the 16 patients who were confirmed to
be smokers (data not shown). The serology for Helicobacter pylori
(HP) infection was available for 41 patients. There were no
significant associations between HP infection and DNA methyl-
ation patterns.
Survival analysis
At the time of analysis (June 2010), the median survival times for
patients classified as having low, medium, and high global DNA
methylation levels were: 17.0 months (95% CI: 10.0–24.0), 12.0
months (95% CI: 5.2–18.8), and 8.4 months (95% CI: 7.0–9.8)
respectively. These results suggest that patients with hypomethy-
lated compared to those with medium or hypermethylated blood
global DNA values have better survival (p=0.04) (Figure 1).
We found that patients classified as having hypomethylation in
p16 based on the mean methylation value across sites and in
particular at site 2 had worse survival than patients with medium
or high methylation levels (Figure 2 and 3). The median survival
times for patients classified as having low, medium, and high p16
DNA methylation levels (the mean across all seven p16 sites) were
9.4 months (95% CI: 7.4–11.4), 19.0 months (95% CI: 5.0–33.0),
and 15 months (95% CI: 3.4–26.6) respectively, (p=0.003)
(Figure 2). The median survival times for patients with low,
medium, and high DNA methylation at site 2 of the p16 gene were
8.5 months (95% CI: 7.0–10.0), 16.2 months (95% CI: 8.3–24.1),
and 14 months (95% CI: 0.1–15.6) respectively, (p=0.02)
(Figure 3).
Multivariate analysis showed that a hypermethylated global
DNA value at diagnosis was a significant independent predictor of
worse survival with a HR of 2.0 (95% CI, 1.1–3.8; p=0.02)
(Table 2). In contrast, medium and high methylation based on the
mean methylation at sites 1–7 of the p16 gene were associated with
better survival with HRs of 0.5 (95% CI, 0.2–0.7; p=0.05) and 0.3
(95% CI, 0.1–0.8; p=0.02) respectively. Other loci were not found
to be significant independent predictors of survival.
Discussion
Few studies have addressed the prognostic value of epigenetic
alterations using pyrosequencing of DNA derived from the whole
blood of patients with solid malignancies [19,24]. To address this
gap in knowledge, we used pyrosequencing to examine whether
whole blood DNA methylation level, both globally (Line-1) and in
the promoter regions of the p16, CDH1, p53, and RUNX3 genes
was associated with prognosis.
Several important observations were made with regard to
methylation patterns and clinicopathological characteristics. Our
data suggest that older GC patients have increased whole blood
Table 1. Primer sequences and PCR conditions for global DNA methylation and specific gene methylation.
Sequence ID
Forward primer
(59 to 39)
Reverse primer
(59 to 39)
Sequencing primer
(59 to 39) PCR PCR conditions
No. CpG
sites
analyzed
Global DNA
Methylation
LINE-1 TTTTGAGTTAG
GTGTGGGATATA
BIOTIN-AAAATCAA
AAAATTCCCTTTC
AGTTAGGTGT
GGGATATAGT
95uC for 5 min (1 cycle),
95uC for 30 s, 50uC for 30 s,
72uC for 30 s (45 cycles),
72uC for 5 min(1cycles), 6uC for ‘
3
Gene-Specific
Methylation
P53 P53BIOTIN-TTAG
GAGTTTATTTAA
TTTAGGGAAG
TATCCAACTTTAT
ACCAAAAACCTC
TCCAAAAAACAAA
TAACTACTAAACTC
95uC for 5 min (1 cycle),
95uC for 1 min, 57uC for 1 min,
72uC for 1 min (50cycle),
72uC for 5 min (1 cycle), 4uC for ‘
4
Gene-Specific
Methylation
CDH1 TTTGATTTTAG
GTTTTAGTGAGT
BIOTIN-ACCACAACC
AATCAACAA
TAGTAATTTTA
GGTTAGAGG
95uC for 5 min (1 cycle),
95uC for 30 s, 55uC for 30 s,
72uC for 30 s (40 cycle),
72uC for 5 min (1 cycle), 6uC for ‘
5
Gene-Specific
Methylation
P16 AGGGGTTGG
TTGGTTATTAG
BIOTIN-CTACCTACTC
TCCCCCTCTC
GGTTGGTTA
TTAGAGGGT
95uC for 5 min (1 cycle),
95uC for 30 s, 58uC for 40 s,
72uC for 30 s (45 cycle),
72uC for 5 min (1 cycle), 6uC for ‘
7
Gene-Specific
Methylation
RUNX3 GGGTATTTTTTA
TTTTTATTGTT
BIOTIN-ACAA
CCCCAA
CTTCCTCTA
GTATTTATTT
TGAAGG
95uC for 5 min (1 cycle),
95uC for 1 min, 52uC for 30 s,
72uC for 30 s (50 cycle),
72uC for 5 min (1 cycle), 4uC for ‘
3
doi:10.1371/journal.pone.0015585.t001
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DNA methylation levels in the promoters of the CDH1, p53, and
RUNX3 genes. Although, this observation has not been reported
before in GC, it is consistent with other studies that have reported
increased methylation levels in other specific genes such as
RASSF1A and hMLH1 in several of cancers including GC
[24,25,26]. moreover, Hypermethylation of tumor suppressor
genes, including p16, has been found in several aging tissues [27].
Gene-specific hypermethylation may be related to increased DNA
damage and increased duration of carcinogen exposure with aging
and could predispose to carcinogenesis.
We observed a significant association between gender and DNA
methylation, with men being more likely than women to have high
whole blood DNA methylation levels in the promoters of the
CDH1, p16, and p53 genes. In contrast, males were more likely to
have reduced global DNA methylation levels. These findings raise
the issue of the biological influence of gender on carcinogenesis.
Several studies suggest that GC growth and migration is
modulated by sex steroid hormones, which is similar to findings
in lung and bladder cancer [19,28].
No previous studies have addressed global and specific DNA
methylation levels in whole blood in association with G.C. cancer
survival. On the other hand, few studies demonstrated the
association between global DNA hypomethylation in target
cancerous or non-target tissues such serum or whole blood and
clinical outcome in other cancers. It was demonstrated that a high
serum LINE-1 hypomethylation level was an independent
predictor of shortened overall survival in 85 patients with
hepatocellualr cancer [29]. Another study included 59 patients
with microdissected ovarian cancer tissue showed that excessive
LINE-1 hypomethylation was associated with a shortened overall
survival [30]. In a large prospective cohort study of health care
professionals, it was shown that global DNA hypomethylation as
measured in LINE-1 is independently associated with poor
survival among patients with colon cancer [31]. In contrast, we
found that patients with low vs. medium or high whole blood
global DNA values had better survival as indicated by the
multivariate analysis showing that hypomethylation is an inde-
pendent prognostic factor as shown in Figure 1 and Table 2. The
reasons behind this unexpected observation is unclear, however,
several postulates can be made. The use of non-target tissue such
as whole blood DNA methylation (global and specific) in GC
patients that can be modulated by various environmental factors
and dietary deficiencies (such folate deficiency) [19]. Therefore, for
whole blood DNA methylation to serve as a biomarker for GC, it
should ideally be correlated with tissue methylation patterns. Two
recent publications in colon cancer showed that there was a
positive relationship between methylation in leukocytes and
colonic tissue in colorectal tumors - albeit inability to distinguish
between disease groups in one of these studies- suggesting potential
usefulness because of ease of accessibility [32–33]. Furthermore,
the use of pyrosequencing as an accurate and quantitative analysis
is different from qualitative techniques used in many of the other
studies.
We found that the patients classified as having high or medium
according to the mean value of all studied p16 promoter CpG sites
(1–7), and in particular at site 2, had better survival than those
classified as having p16 low values and shown in Figure 2 and 3. In
multivariate analysis, overall high methylation value at sites 1–7 in
the p16 gene, in particular, was found to have independent
prognostic significance as shown in Table 2. There were no
previous studies that examined the prognostic significance of
whole blood DNA in GC. Therefore, with the paucity of studies,
the relationship between methylation status and prognosis remains
a controversial area even when studied in gastric cancer tissue.
Kissa et al demonstrated that RASSFIA, APC, and RAR-b2
promoter hypermethylation were significantly correlated with
improved survival in GC patients [34]. Moreover, An et al showed
that concordant hypermethylation of multiple genes (p16,
hMLH1, MINT1, MINT2, MINT25, and MINT31) was
associated with better survival [35]. It has been postulated that
GC tumors with epigenetic alterations are less aggressive and
patients with these types of tumors have improved prognosis
Figure 1. Cumulative survival of GC patients according to whole global (Line-1) blood DNA methylation values.
doi:10.1371/journal.pone.0015585.g001
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compared to those with tumors that harbor other genetic
alterations [34]. Furthermore, it has been shown in head and
neck cancer that patients with CDH1 hypermethylation have
significantly better overall survival than those without hyper-
methylation [36]. Marsit et al postulated that inactivation of the
CDH1 gene by hypermethylation may lead to a less biologically
aggressive tumor phenotype and greater sensitivity to treatment
thereby providing a survival advantage [36]. In contrast Zazula et
al and Graziano et al showed that CDH1 promoter hypermethy-
lation was associated with worse prognosis [15,37]. Studies
have shown that hypermethylation of the p16 promoter
results in worse survival in high-intermediate-risk and high-risk
diffuse large B cell lymphoma and colorectal cancer patients
[38,39].
Figure 2. Cumulative survival of GC patients according to P16 (mean value of 7 sites) whole blood DNA methylation values.
doi:10.1371/journal.pone.0015585.g002
Figure 3. Cumulative survival of GC patients according to P16 (site 1) whole blood DNA methylation values.
doi:10.1371/journal.pone.0015585.g003
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The correlation between site-specific DNA methylation levels
and poor prognostic features such as the depth of tumor invasion
and lymph node metastasis is of particular interest given the
survival patterns described above and the role of apoptotic and
adhesion regulating genes play in tumor growth and invasion. We
found that hypomethylation of several specific gene promoter sites
in whole blood DNA were associated with poor prognostic
features. In particular, hypomethylation of p53 at sites 1, 3, 4, and
overall, and of RUNX3 at site 2 was associated with lymph node
involvement. Advanced T stage presentation was associated with
hypomethyaltion of RUNX3 at site 3. Although, promoter region
hypermethylation is the prime mechanism of transcriptional
silencing of various tumor suppressors involved in carcinogenesis,
it is increasingly recognized that promoter region hypomethylation
also alter the transcriptional activation of different genes including
MAGE, S100A4, and synuclein c [40,41,42]. Moreover, Sato et al
demonstrated that gene hypomethylation associated with overex-
pression of multiple genes that contributes to carcinogenesis in
pancreatic adenocarcinoma [43]. Lin et al suggested that of the
extent of hypomethylation correlates with poor prognostic features
in some cancers[29]. Taken together, the current study suggests
that promoter-specific low methylation levels results in worse
survival in some genes such as p16 with correlation- in other
genes- with poor prognostic features possibly by altering affected
gene expression. However, it should be highlighted that our
understanding of the role of specific promoter hypomethylation in
carcinogenesis and prognosis is limited, particularly in whole
blood.
In conclusion, our preliminary analysis suggests that epigenetic
changes detected in whole blood DNA are associated with several
prognostic factors and therefore these results may benefit GC
patients in terms of treatment protocol design and follow-up.
Moreover, the current study demonstrates the feasibility of
pyrosequencing for quantifying DNA methylation and may thus
serve as a non-invasive prognostic tool.
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